This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: A2a Pharmaceuticals, Inc., Oncocube Therapeutics LLC. Active years: 2023.
Company Filing History:
1 out of 2 
1 out of 2 Years Active: 2023
Title: The Innovative Journey of Ozge Akbulut
Introduction
Ozge Akbulut is an accomplished inventor based in Ankara, Turkey. His significant contributions to the field of oncology have led to the development of a novel anticancer drug candidate. With a strong background in pharmaceutical research, Akbulut has secured a patent that showcases his innovative spirit and commitment to advancing cancer treatments.
Latest Patents
Akbulut holds a patent for a highly potent TACC3 inhibitor known as BO-264. This invention involves a new inhibitor chemotype, 3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl) isoxazol-5-amine, which targets the TACC3 protein with high efficacy. As a mitotic blocker, this compound shows promising potential for treating breast cancer and possibly other types of cancer. The patent highlights the importance of his research in the fight against cancer and the ongoing search for effective therapies.
Career Highlights
Throughout his career, Ozge Akbulut has collaborated with renowned organizations in the pharmaceutical sector, including A2A Pharmaceuticals, Inc. and Oncocube Therapeutics LLC. His work at these companies has positioned him at the forefront of cancer research, leading to impactful advancements in drug development.
Collaborations
In his journey, Akbulut has had the opportunity to work alongside talented professionals, including his coworkers Erden Banoglu and Burcu Caliskan. These collaborations have enriched his research, enabling him to contribute to the innovative landscape of cancer treatment more effectively.
Conclusion
Ozge Akbulut's contributions to the field of oncology, particularly through his patent for the TACC3 inhibitor, underscore his role as a significant innovator in cancer therapeutics. His collaborations and industry experience continue to pave the way for future advancements, making him a noteworthy figure in the realm of pharmaceutical innovation.